<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03431649</url>
  </required_header>
  <id_info>
    <org_study_id>TAshirley</org_study_id>
    <nct_id>NCT03431649</nct_id>
  </id_info>
  <brief_title>Efficacy of Beraprost in Lowering Pulmonary Arterial Pressure in Children</brief_title>
  <official_title>Efficacy of Beraprost in Lowering Pulmonary Arterial Pressure in Pulmonary Arterial Hypertension Children Associated With Left to Right Shunt Congenital Heart Defect</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dr. Soetomo General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dr. Soetomo General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To analyze the efficacy of beraprost and sildenafil for treatment of pulmonary hypertension
      in children with left to right shunt.

      analyze the efficacy and side effects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Eligibility criteria:

      Inclusion:

        1. children aged 1-17 years with left to right shunt, diagnosed as pulmonary hypertension.

        2. free from chronic pulmonary disease

        3. never performed any cardiac surgical

        4. never got any treatment for PH

        5. agree to enroll in this study. Exclusion

      1. suffer from portal hypertension, HIV and connective tissue disease 2. under interferon
      therapy.

      Outcome measure:

      Pulmonary artery pressure
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 1, 2017</start_date>
  <completion_date type="Actual">October 30, 2017</completion_date>
  <primary_completion_date type="Actual">July 30, 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
    <masking_description>the researchers don't know which drug taken by the patient and don't know the previous PA pressure</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy of Beraprost, Sildenafil and comparison between both drugs in lowering pulmonary arterial pressure</measure>
    <time_frame>12 weeks</time_frame>
    <description>Measuring mPAP (pre-post therapy) via echocardiography before and after consuming sildenafil or beraprost</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Emergent Adverse Events</measure>
    <time_frame>12 weeks</time_frame>
    <description>adverse event reported by patients and during weekly examination after consuming Beraprost or Sildenafil: hypotension, dizzy, headache, flushing, bleeding</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Pediatric Pulmonary Hypertension</condition>
  <arm_group>
    <arm_group_label>Beraprost Sodium</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Beraprost 1mcg/kg/day, divided in 3 doses orally patient was followed up for 12 weeks, then echocardiography evaluation was performed in patient completed the study.
22 patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sildenafil citrate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sildenafil 0.4 mg/kg/time, 4 times daily per oral patient was followed up for 12 weeks, then echocardiography evaluation was performed in patient completed the study.
20 patients</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Beraprost Sodium</intervention_name>
    <description>1 mcg /kgbw daily, divided in three dosages orally for 12 weeks</description>
    <arm_group_label>Beraprost Sodium</arm_group_label>
    <other_name>Dorner</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sildenafil Citrate</intervention_name>
    <description>0.4 mg/kgbw each time, 4 times in a day orally for 12 weeks</description>
    <arm_group_label>Sildenafil citrate</arm_group_label>
    <other_name>Viagra</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  diagnosed as pulmonary hypertension with left to right shunt CHD (VSD, ASD, PDA and
             combination)

          -  agree to enroll in this study

        Exclusion Criteria:

          -  suffer from chronic lung disease

          -  suffer from soft tissue tumor, HIV/AIDS

          -  under interferon therapy

          -  already performed any cardiac surgery

          -  already got anti-PH remedy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mahrus Rachman, MD</last_name>
    <role>Study Director</role>
    <affiliation>Dr. Soetomo General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dr. Soetomo General Hospital</name>
      <address>
        <city>Surabaya</city>
        <state>East Java</state>
        <country>Indonesia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Indonesia</country>
  </location_countries>
  <reference>
    <citation>Limsuwan A, Pienvichit P, Khowsathit P. Beraprost therapy in children with pulmonary hypertension secondary to congenital heart disease. Pediatr Cardiol. 2005 Nov-Dec;26(6):787-91.</citation>
    <PMID>16132278</PMID>
  </reference>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 29, 2017</study_first_submitted>
  <study_first_submitted_qc>February 12, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 13, 2018</study_first_posted>
  <last_update_submitted>February 12, 2018</last_update_submitted>
  <last_update_submitted_qc>February 12, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 13, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Dr. Soetomo General Hospital</investigator_affiliation>
    <investigator_full_name>Dr. dr. Mahrus A. Rahman Sp.A(K)</investigator_full_name>
    <investigator_title>Doctor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Hypertension, Pulmonary</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Citric Acid</mesh_term>
    <mesh_term>Beraprost</mesh_term>
    <mesh_term>Sildenafil Citrate</mesh_term>
    <mesh_term>Epoprostenol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

